E
Voyageur Pharmaceuticals Ltd.
VYYRF
$0.0991
-$0.0069-6.51%
E
Sell
12/27/2024Downgrade
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to E+ from D- on 12/27/2024 due to a significant decline in the valuation index.
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to E+ from D- on 12/27/2024 due to a significant decline in the valuation index.
D
Sell
12/12/2024Upgraded
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D- from E+ on 12/12/2024 due to a significant increase in the valuation index.
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D- from E+ on 12/12/2024 due to a significant increase in the valuation index.
E
Sell
11/27/2024Downgrade
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to E+ from D- on 11/27/2024 due to a decline in the volatility index, total return index and solvency index. Debt to equity increased from 0.03 to 0.04, and the quick ratio declined from 0.04 to 0.03.
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to E+ from D- on 11/27/2024 due to a decline in the volatility index, total return index and solvency index. Debt to equity increased from 0.03 to 0.04, and the quick ratio declined from 0.04 to 0.03.
D
Sell
9/19/2024Upgraded
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D- from E+ on 9/19/2024 due to a noticeable increase in the total return index and volatility index.
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D- from E+ on 9/19/2024 due to a noticeable increase in the total return index and volatility index.
E
Sell
3/28/2024Downgrade
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to E+ from D- on 3/28/2024 due to a large decline in the growth index, valuation index and solvency index. Earnings per share declined from -$0.0007 to -$0.0016, EBIT declined 98.18% from -$82.3 to -$163.1, and debt to equity increased from 0.02 to 0.03.
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to E+ from D- on 3/28/2024 due to a large decline in the growth index, valuation index and solvency index. Earnings per share declined from -$0.0007 to -$0.0016, EBIT declined 98.18% from -$82.3 to -$163.1, and debt to equity increased from 0.02 to 0.03.
D
Sell
3/6/2024Upgraded
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D- from E+ on 3/6/2024 due to an increase in the valuation index.
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D- from E+ on 3/6/2024 due to an increase in the valuation index.
E
Sell
12/22/2023Downgrade
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to E+ from D- on 12/22/2023 due to a noticeable decline in the solvency index, valuation index and total return index. Debt to equity increased from 0.01 to 0.02, and the quick ratio declined from 0.44 to 0.08.
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to E+ from D- on 12/22/2023 due to a noticeable decline in the solvency index, valuation index and total return index. Debt to equity increased from 0.01 to 0.02, and the quick ratio declined from 0.44 to 0.08.
D
Sell
10/16/2023Upgraded
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D- from E+ on 10/16/2023 due to an increase in the valuation index.
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D- from E+ on 10/16/2023 due to an increase in the valuation index.
E
Sell
9/20/2023Downgrade
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to E+ from D- on 9/20/2023 due to a large decline in the growth index, volatility index and valuation index. EBIT declined 78.18% from -$238.8 to -$425.5, earnings per share declined from -$0.0022 to -$0.0035, and operating cash flow declined 2.12% from -$348.6 to -$356.
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to E+ from D- on 9/20/2023 due to a large decline in the growth index, volatility index and valuation index. EBIT declined 78.18% from -$238.8 to -$425.5, earnings per share declined from -$0.0022 to -$0.0035, and operating cash flow declined 2.12% from -$348.6 to -$356.
D
Sell
6/28/2023Upgraded
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D- from E+ on 6/28/2023 due to an increase in the valuation index and volatility index.
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D- from E+ on 6/28/2023 due to an increase in the valuation index and volatility index.
E
Sell
6/13/2023Downgrade
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to E+ from D- on 6/13/2023 due to a decline in the solvency index, valuation index and total return index.
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to E+ from D- on 6/13/2023 due to a decline in the solvency index, valuation index and total return index.
D
Sell
3/29/2023Upgraded
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D- from E+ on 3/29/2023 due to an increase in the valuation index.
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D- from E+ on 3/29/2023 due to an increase in the valuation index.
E
Sell
3/14/2023Downgrade
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index.
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index.
D
Sell
2/9/2023Upgraded
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to E+ from D on 2/8/2023 due to a decline in the solvency index, total return index and volatility index.
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to E+ from D on 2/8/2023 due to a decline in the solvency index, total return index and volatility index.
D
Sell
4/29/2022Upgraded
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D from D- on 4/29/2022 due to an increase in the valuation index and solvency index.
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D from D- on 4/29/2022 due to an increase in the valuation index and solvency index.
D
Sell
4/20/2022Downgrade
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to D- from D on 4/20/2022 due to a decline in the valuation index, growth index and total return index. Operating cash flow declined 56.26% from -$237.1 to -$370.5, EBIT declined 41.41% from -$278.9 to -$394.4, and earnings per share declined from -$0.0033 to -$0.0037.
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to D- from D on 4/20/2022 due to a decline in the valuation index, growth index and total return index. Operating cash flow declined 56.26% from -$237.1 to -$370.5, EBIT declined 41.41% from -$278.9 to -$394.4, and earnings per share declined from -$0.0033 to -$0.0037.
D
Sell
11/9/2021Upgraded
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D from E+ on 11/09/2021.
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index.
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index.
D
Sell
2/3/2021Upgraded
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D from D- on 2/3/2021 due to a large increase in the total return index and volatility index.
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D from D- on 2/3/2021 due to a large increase in the total return index and volatility index.
D
Sell
11/5/2020Downgrade
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to D- from D on 11/5/2020 due to a noticeable decline in the total return index and volatility index.
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to D- from D on 11/5/2020 due to a noticeable decline in the total return index and volatility index.
D
Sell
7/24/2020Upgraded
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D from D- on 7/24/2020 due to a noticeable increase in the growth index and volatility index. Operating cash flow increased 89.97% from -$179.4 to -$18, EBIT increased 69.4% from -$310.1 to -$94.9, and earnings per share increased from -$0.0046 to -$0.0028.
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D from D- on 7/24/2020 due to a noticeable increase in the growth index and volatility index. Operating cash flow increased 89.97% from -$179.4 to -$18, EBIT increased 69.4% from -$310.1 to -$94.9, and earnings per share increased from -$0.0046 to -$0.0028.
D
Sell
7/23/2020Downgrade
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to D- from D on 7/23/2020 due to a decline in the volatility index and total return index.
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to D- from D on 7/23/2020 due to a decline in the volatility index and total return index.
D
Sell
7/8/2020Upgraded
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D from D- on 7/8/2020 due to an increase in the total return index, valuation index and volatility index.
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D from D- on 7/8/2020 due to an increase in the total return index, valuation index and volatility index.
D
Sell
6/23/2020Downgrade
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to D- from D on 6/23/2020 due to a noticeable decline in the total return index and valuation index.
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to D- from D on 6/23/2020 due to a noticeable decline in the total return index and valuation index.
D
Sell
6/5/2020Upgraded
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D from D- on 6/5/2020 due to an increase in the total return index, valuation index and volatility index.
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D from D- on 6/5/2020 due to an increase in the total return index, valuation index and volatility index.
D
Sell
5/21/2020Downgrade
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to D- from D on 5/21/2020 due to a decline in the growth index, valuation index and volatility index.
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to D- from D on 5/21/2020 due to a decline in the growth index, valuation index and volatility index.
D
Sell
5/1/2020Upgraded
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D from D- on 5/1/2020 due to an increase in the volatility index, total return index and growth index.
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D from D- on 5/1/2020 due to an increase in the volatility index, total return index and growth index.
D
Sell
11/15/2019Downgrade
Voyageur Minerals Ltd. (VYYRF) was downgraded to D- from D on 11/15/2019 due to a major decline in the growth index, total return index and volatility index. EBIT declined 100.65% from -$76.5 to -$153.5, earnings per share declined from -$0.0015 to -$0.0028, and operating cash flow declined 37.34% from -$108.2 to -$148.6.
Voyageur Minerals Ltd. (VYYRF) was downgraded to D- from D on 11/15/2019 due to a major decline in the growth index, total return index and volatility index. EBIT declined 100.65% from -$76.5 to -$153.5, earnings per share declined from -$0.0015 to -$0.0028, and operating cash flow declined 37.34% from -$108.2 to -$148.6.
D
Sell
7/26/2019Upgraded
Voyageur Minerals Ltd. (VYYRF) was upgraded to D from D- on 7/26/2019 due to a noticeable increase in the growth index, total return index and solvency index. The quick ratio increased from 0.11 to 0.16, debt to equity declined from 0.39 to 0.23, and EBIT increased 28.24% from -$106.6 to -$76.5.
Voyageur Minerals Ltd. (VYYRF) was upgraded to D from D- on 7/26/2019 due to a noticeable increase in the growth index, total return index and solvency index. The quick ratio increased from 0.11 to 0.16, debt to equity declined from 0.39 to 0.23, and EBIT increased 28.24% from -$106.6 to -$76.5.
D
Sell
5/2/2019Downgrade
Voyageur Minerals Ltd. (VYYRF) was downgraded to D- from D on 5/2/2019 due to a decline in the efficiency index, solvency index and valuation index. The quick ratio declined from 0.4 to 0.11, debt to equity increased from 0.29 to 0.39, and total capital declined 19.22% from $522.5 to $422.1.
Voyageur Minerals Ltd. (VYYRF) was downgraded to D- from D on 5/2/2019 due to a decline in the efficiency index, solvency index and valuation index. The quick ratio declined from 0.4 to 0.11, debt to equity increased from 0.29 to 0.39, and total capital declined 19.22% from $522.5 to $422.1.
D
Sell
1/7/2019Upgraded
Voyageur Minerals Ltd. (VYYRF) was upgraded to D from D- on 1/7/2019 due to a noticeable increase in the efficiency index, volatility index and valuation index. Total capital increased 416.72% from $99.9 to $516.2, and net income increased 146.72% from -$120.5 to $56.3.
Voyageur Minerals Ltd. (VYYRF) was upgraded to D from D- on 1/7/2019 due to a noticeable increase in the efficiency index, volatility index and valuation index. Total capital increased 416.72% from $99.9 to $516.2, and net income increased 146.72% from -$120.5 to $56.3.
D
Sell
7/2/2018Upgraded
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D- from E on 07/02/2018.
Voyageur Pharmaceuticals Ltd. (VYYRF) was upgraded to D- from E on 07/02/2018.
E
Sell
4/30/2018Downgrade
Voyageur Minerals Ltd. (VYYRF) was downgraded to E from E+ on 4/30/2018 due to a significant decline in the efficiency index, volatility index and valuation index. Net income declined 2.84% from -$109.2 to -$112.3.
Voyageur Minerals Ltd. (VYYRF) was downgraded to E from E+ on 4/30/2018 due to a significant decline in the efficiency index, volatility index and valuation index. Net income declined 2.84% from -$109.2 to -$112.3.
E
Sell
4/2/2018Upgraded
Voyageur Minerals Ltd. (VYYRF) was upgraded to E+ from E on 4/2/2018 due to a major increase in the total return index.
Voyageur Minerals Ltd. (VYYRF) was upgraded to E+ from E on 4/2/2018 due to a major increase in the total return index.
E
Sell
1/16/2018None
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to E from U on 01/16/2018.
Voyageur Pharmaceuticals Ltd. (VYYRF) was downgraded to E from U on 01/16/2018.
OTC PK
03/11/2025 9:30AM Eastern
Quotes delayed
